This page contains affiliate links. We may earn a commission at no extra cost to you.

$15–$35 for a 60-day supply

Check Price on Amazon
Evidence: Strong — multiple European RCTs (ALADIN I, II, III; SYDNEY I, II; NATHAN I, II) show statistically significant pain reduction at 600 mg daily. FDA-recognized as an approved treatment in Germany. Recommended by several professional neuropathy guidelines as an adjunctive option.

Alpha lipoic acid (ALA) is a powerful antioxidant produced naturally in small amounts by the body and present in trace quantities in certain foods. It occupies a unique position in neuropathy research: it is FDA-recognized as an approved treatment for diabetic neuropathy in Germany and has been used there as a standard medical therapy since the 1960s. Multiple European randomized controlled trials — primarily the ALADIN, SYDNEY, and NATHAN series — have established that ALA supplementation at 600 mg daily significantly reduces neuropathic pain symptoms and may partially improve nerve function measures in diabetic peripheral neuropathy. It remains one of the most evidence-supported supplements for nerve pain and is widely recommended by neurologists and integrative medicine practitioners as an adjunct to conventional treatment. As with all supplements, consult your physician before starting.

How It Works

Alpha lipoic acid functions as both a water-soluble and fat-soluble antioxidant — a rare dual solubility that allows it to protect both the aqueous interior and lipid membranes of nerve cells. In the context of diabetic neuropathy, chronically elevated blood sugar drives the production of reactive oxygen species (free radicals) that damage nerve fiber membranes, impair mitochondrial function, and reduce blood flow to peripheral nerves. ALA neutralizes these free radicals directly and also regenerates other antioxidants — particularly vitamins C and E and glutathione — restoring a broader antioxidant network.

Beyond antioxidant activity, ALA improves insulin sensitivity, which may help reduce the metabolic stress underlying diabetic neuropathy. It also increases production of nerve growth factor (NGF), a protein essential for the survival and maintenance of sensory nerve fibers. Research suggests ALA may improve endoneural blood flow — the microvascular supply that delivers oxygen and nutrients to nerve axons — addressing the ischemic component of diabetic nerve damage. The combination of antioxidant, metabolic, and neurotrophic mechanisms gives ALA a rationale that goes beyond simple symptom masking.

What the Research Says

The ALADIN trials (Alpha Lipoic Acid in Diabetic Neuropathy), conducted in Germany throughout the 1990s, provided the initial evidence base that established ALA as a meaningful treatment for diabetic peripheral neuropathy. ALADIN I found that 600 mg daily of IV ALA for three weeks significantly reduced neuropathic pain compared to placebo. Subsequent trials shifted to oral administration and longer durations. The SYDNEY II trial — a 5-week oral RCT of 600 mg ALA daily — found a 51 percent reduction in neuropathic symptom score from baseline versus 32 percent in the placebo group, a clinically meaningful difference.

The NATHAN trials evaluated long-term outcomes over four years, finding that while pain improvement was meaningful, the effect on objective nerve function measures (nerve conduction velocity, vibration threshold) was modest. This suggests ALA is most effective as a pain-reducing agent rather than a nerve-regenerating one at oral doses, though improved neurological deficits have been reported with IV administration. A 2012 systematic review and meta-analysis in Diabetic Medicine confirmed that ALA produced significantly greater pain reduction than placebo across multiple trials.

For neuropathy types other than diabetic — including idiopathic, small fiber, and CIPN — evidence is more limited but the antioxidant rationale is applicable to any neuropathy involving oxidative stress. Some practitioners use ALA across neuropathy types with this reasoning, though direct trial data are largely absent.

How to Take It

For maximum absorption, ALA should be taken on an empty stomach — food, particularly protein and fat, significantly reduces its bioavailability. Taking it 30 to 60 minutes before a meal is the standard guidance. At 600 mg daily, a single morning dose is common and simpler to maintain than split dosing. For patients using the higher 1,200 mg daily dose that some protocols employ, splitting into two 600 mg doses (morning and evening, both on an empty stomach) is recommended.

Be aware that ALA may lower blood sugar, particularly in diabetic patients. For those on insulin or blood sugar-lowering medications, monitoring blood sugar more frequently when starting ALA is prudent, and discussing the addition of ALA with your diabetes care provider before starting is important. Some patients report mild gastrointestinal discomfort (nausea, reflux) when starting ALA, which often resolves after a few days or with dose reduction. If you take thyroid medications, take ALA and thyroid medication at different times of day, as ALA may affect thyroid hormone metabolism.

What to Look For When Buying

Not all ALA supplements are created equal. The commercially available form is typically racemic ALA — a 50/50 mixture of the R-isomer (the naturally occurring, biologically active form) and the S-isomer (synthetic, with lower biological activity). Some products specifically offer R-ALA, which has approximately twice the bioavailability of racemic ALA — meaning 300 mg R-ALA may be roughly equivalent to 600 mg racemic ALA.

Look for products that clearly specify the form of ALA (racemic vs. R-ALA), have third-party testing certification (NSF, USP, or Informed Sport), and do not include excessive additives. Capsule forms are generally preferable to tablets for better dissolution and absorption. Reputable brands with third-party certification include Jarrow Formulas, Thorne Research, Life Extension, and Doctor’s Best. Price should not be the primary purchase criterion — verified purity and dose accuracy matter more for a supplement you will take daily for months.

Pros

• Strongest evidence base of any supplement for diabetic peripheral neuropathy pain
• Dual antioxidant mechanism addresses both water-soluble and fat-soluble components of nerve cell damage
• May improve insulin sensitivity as an additional benefit in diabetic patients
• Well-tolerated by most patients at 600 mg daily
• Relatively affordable, particularly when purchased from reputable third-party-certified brands

Cons

• May lower blood sugar — diabetic patients on medications require monitoring and physician coordination
• Absorption is significantly reduced when taken with food
• Effects on objective nerve function are more modest than effects on pain symptoms
• R-ALA supplements are more expensive and less stable than racemic ALA

Frequently Asked Questions

How long does it take for alpha lipoic acid to work for neuropathy?

In clinical trials, pain reductions were measured at 3 to 5 weeks of daily use. Many patients report initial changes — often a reduction in burning pain or improved sleep — within 3 to 6 weeks. For meaningful, sustained benefit, a minimum 3-month consistent trial is appropriate. Some practitioners recommend ongoing use as long as it continues to help, as there is no established safety concern with long-term ALA supplementation at 600 mg daily.

Is R-ALA worth the extra cost over regular ALA?

R-ALA is more bioavailable — roughly twice as much as racemic ALA — meaning you absorb more active compound per milligram. However, R-ALA is also less stable (more prone to clumping and degradation if exposed to heat or humidity) and more expensive. For most patients, quality racemic ALA at 600 mg from a verified manufacturer is a practical and cost-effective starting point. R-ALA stabilized with biotin-free sodium (sodium R-ALA) is a more stable alternative if you prefer the R-form.

Can I take ALA if I’m not diabetic?

Yes. Alpha lipoic acid is not restricted to diabetic patients — its antioxidant mechanisms are relevant to any neuropathy involving oxidative stress, and it is generally safe for most adults. However, the clinical evidence base is primarily from diabetic neuropathy trials, so the expected benefit in non-diabetic neuropathy is less well-established. Consult your doctor to discuss whether ALA is appropriate for your specific neuropathy type.

Can alpha lipoic acid be taken with other neuropathy supplements?

ALA is commonly combined with benfotiamine (B1), methylcobalamin (B12), and acetyl-L-carnitine in integrative neuropathy protocols. These supplements work through complementary mechanisms and there are no known harmful interactions between them. Avoid taking ALA within 2 hours of thyroid medication. Inform all your prescribing physicians about your complete supplement regimen to allow monitoring for any blood sugar or other effects.

Buy on Amazon — $15–$35 for a 60-day supply